The finding of nuclear YAP1 staining in human RIT1-mutant tumors suggests that RIT1 variants may be most oncogenic in the context of YAP1 activation, and therefore targeting YAP/TEAD activity should be explored as a strategy to suppress RIT1-mutant lung cancer. This evidence concerns the gene RIT1 and lung carcinoma.